Atrial functional mitral regurgitation Atrial functional mitral regurgitation occurs secondary to left atrial disease, without left ventricular dilatation and intrinsic mitral valve disease. Atrial functional MR typically occurs
Phosphodiesterase-9 inhibitors for the treatment of heart failure? Phosphodiesterase-9 (PDE9) has the highest binding affinity among phosphodiesterases with cyclic guanosine monophosphate [1]. Cardioprotective effects of natriuretic peptides released
Transcatheter Edge-to-Edge Repair (TEER) of Mitral Valve Transcatheter Edge-to-Edge Repair (TEER) of the mitral valve is done for treatment of mitral regurgitation [1]. Anterior and posterior leaflets of
Contrasting results of REDUCE-IT and STRENGTH trials of Omega 3 Contrasting results of REDUCE-IT [1] and STRENGTH [2] trials of Omega 3 fatty acid preparations have caught the
What is Wellens’ syndrome? The original description of Wellens’ syndrome dates back to 1982 in which they identified a subgroup of patients admitted with unstable angina who are
Periodontal disease linked to heart failure – New study report Periodontal disease is known to be associated with coronary artery disease as well as poses a risk for
hs-CRP as a risk assessment tool for cardiovascular disease It is often mentioned that almost half of first cardiovascular events occur in individuals with no known risk factors.
Intravenous acetazolamide for acute decompensated heart failure – ADVOR Study Acetazolamide in Decompensated Heart Failure With Volume OveRload (ADVOR) study assessed whether intravenous acetazolamide can improve the efficacy
Finerenone, a non-steroidal MRA Finerenone is a nonsteroidal, selective mineralocorticoid receptor antagonist. Finerenone is thought to have lower risk of hyperkalemia and renal issues compared to other MRAs.
DIAMOND trial: Patiromer for management of hyperkalemia in HFrEF Patiromer is a nonabsorbed potassium binder used in the treatment of hyperkalemia. Earlier it was tested in patients with
